Physician profile
Michael Wolfson
NPI 1073580940
$12,383.66
in general payments reported to CMS, 2019-2025
40 companies · $2,805 in 2025
The $2,805 reported for 2025 was more than what 86% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,099 · 2020: $790 · 2021: $1,448 · 2022: $1,652 · 2023: $2,178 · 2024: $2,410 · 2025: $2,805.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,371 · Education: $22.67.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,371.08 |
| Education | $22.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,216.30 | 2019-2025 | Rinvoq, Skyrizi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,396.58 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Takeda Pharmaceuticals U.S.A., INC. | $1,304.59 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Celgene Corporation | $1,189.20 | 2021-2024 | Zeposia |
| Janssen Biotech, INC. | $1,140.43 | 2019-2025 | Tremfya, Stelara |
| Pfizer INC. | $757.68 | 2019-2025 | |
| Qol Medical, LLC | $383.68 | 2020-2025 | Sucraid, Sucraid |
| Ardelyx, INC. | $350.76 | 2023-2025 | Ibsrela |
| Genzyme Corporation | $348.45 | 2022-2025 | |
| Madrigal Pharmaceuticals | $338.34 | 2024-2025 | Rezdiffra, Resmetirom |
| Lilly USA, LLC | $336.37 | 2023-2025 | Omvoh |
| Intercept Pharmaceuticals, INC. | $320.78 | 2019-2024 | Ocaliva |
| Regeneron Healthcare Solutions, INC. | $316.15 | 2022-2025 | Dupixent |
| Phathom Pharmaceuticals, INC. | $243.64 | 2024-2025 | Voquezna |
| Gilead Sciences, INC. | $239.65 | 2019-2025 | Epclusa |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $229.88 | 2021-2025 | Injectafer |
| Merck Sharp & Dohme LLC | $211.05 | 2020-2024 | Dificid |
| Ferring Pharmaceuticals INC. | $190.82 | 2019-2024 | Rebyota |
| Amgen INC. | $95.35 | 2020-2025 | Uplizna, Avsola, Amjevita |
| Ironwood Pharmaceuticals, INC | $91.50 | 2019-2023 | Linzess |
| Braintree Laboratories, INC. | $70.07 | 2019-2023 | Sutab |
| Ipsen Biopharmaceuticals, INC | $64.10 | 2024-2025 | Iqirvo |
| Evoke Pharma, INC. | $63.39 | 2023-2025 | Gimoti |
| Celltrion USA INC. | $54.35 | 2023-2024 | Vegzelma, Yuflyma |
| Nestle Healthcare Nutrition INC. | $52.74 | 2021-2022 | |
| Redhill Biopharma INC. | $48.20 | 2020-2023 | Movantik, Talicia, Aemcolo |
| Ucb, INC. | $45.05 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.43 | 2024 | Cyltezo |
| Organon LLC | $28.58 | 2023 | Renflexis, Hadlima |
| Alexion Pharmaceuticals, INC. | $24.94 | 2019 | |
| Allergan, INC. | $24.38 | 2019 | |
| Aimmune Therapeutics, INC. | $22.08 | 2025 | Zenpep |
| Fresenius Kabi USA, LLC | $21.95 | 2023 | Idacio |
| Alfasigma USA, INC. | $21.89 | 2020 | |
| Exact Sciences Corporation | $20.24 | 2025 | Cologuard Collection Kit |
| Capsovision, INC. | $20.08 | 2024 | Capsocam Plus |
| Albireo Pharma, INC. | $18.37 | 2023 | Bylvay |
| Inspire Medical Systems, INC. | $17.95 | 2025 | Inspire |
| Endo Pharmaceuticals INC. | $15.44 | 2019 | |
| Dova Pharmaceuticals | $15.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Wolfson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.